![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lunglife Ai Inc | LSE:LLAI | London | Ordinary Share | ORD USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -0.69% | 14.40 | 13.80 | 15.00 | 14.50 | 14.40 | 14.50 | 19,886 | 09:42:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLLAI
RNS Number : 0239Y
LungLife AI, INC
02 September 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
New York State approves LungLB (R) for commercial testing
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the New York State Department of Health ("NYSDOH") has awarded LungLife a Clinical Laboratory Evaluation Program ("CLEP") permit following their recent on-site audit, during which there were no deficiencies found.
The CLEP permit allows LungLife to perform clinical utility studies and offer the LungLB(R) test commercially in New York state, in addition to 46 other states permitted by the Company's existing Clinical Laboratory Improvement Amendments ("CLIA") certification.
This is an important step in LungLife's commercialisation plan, given its relationship with the Icahn School of Medicine at Mount Sinai in New York, a key site in the ongoing pivotal validation trial, and from which the Company is now able to accept study participants in future utility studies. Securing a CLEP permit is a requirement to consider participants from New York state in the utility studies planned for 2023, from which the Company expects first nominal revenues.
The audit was performed to ensure that the premises, laboratory practice, equipment, personnel, and record-keeping methods meet state requirements. Issuance of the CLEP permit follows a rigorous, independent scientific review of both analytical and clinical data for LungLB(R), as well as evaluation of adherence to the Company's quality management system.
Lara Baden, VP of Clinical Operations for LungLife said: "We are pleased to have received a CLEP permit from the NYSDOH. Not only does this provide further validation of our best-in-class quality system, but also approval of the LungLB(R) test means that LungLife can offer this service to physicians in New York state who evaluate indeterminate lung nodules for early cancer detection."
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO Via Walbrook PR David Anderson, CFO Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970 & Broker) Daniel Adams / Virginia Bull / Cameron MacRitchie Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 / Marriage 0 7867 984 082
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBKDBNOBKDPCK
(END) Dow Jones Newswires
September 02, 2022 02:01 ET (06:01 GMT)
1 Year Lunglife Ai Chart |
1 Month Lunglife Ai Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions